Abstract
Heat shock proteins (HSPs) are ubiquitous and evolutionary conserved proteins induced by cell stress. HSP60, in particular, is a typical mitochondrial molecular chaperone that is known to assist nascent polypeptides to reach a native conformation. HSP60 is also known to interact with HSP10. In the last decade, HSP60 has been detected in the cytosol, the cell surface, the extracellular space, and biological fluids. HSP60 elicits potent proinflammatory response in cells of the innate immune system and serves as a danger signal of stressed or damaged cells. As cytosolic HSP60 levels gradually increase or decrease during carcinogenesis in various organs, HSP60 can be used as a biomarker for the diagnosis and prognosis of preneoplastic and neoplastic lesions. In this review, we summarize recent discoveries on the important roles of HSP60 in various diseases ranging from autoimmune diseases to tumors. Furthermore, small molecules targeting HSP60, which were the target of intensive investigations in the last few years, are also summarized. The possibility of utilizing HSP60 as a new drug target for the treatment of certain diseases is examined.
Keywords: HSP60, molecular chaperone, apoptosis, proinflammatory response, biomarker, carcinogenesis, inhibitor, cell stress, diagnosis, prognosis.
Current Pharmaceutical Design
Title:HSP60 as a Drug Target
Volume: 19 Issue: 3
Author(s): Hiroyuki Nakamura and Hidemitsu Minegishi
Affiliation:
Keywords: HSP60, molecular chaperone, apoptosis, proinflammatory response, biomarker, carcinogenesis, inhibitor, cell stress, diagnosis, prognosis.
Abstract: Heat shock proteins (HSPs) are ubiquitous and evolutionary conserved proteins induced by cell stress. HSP60, in particular, is a typical mitochondrial molecular chaperone that is known to assist nascent polypeptides to reach a native conformation. HSP60 is also known to interact with HSP10. In the last decade, HSP60 has been detected in the cytosol, the cell surface, the extracellular space, and biological fluids. HSP60 elicits potent proinflammatory response in cells of the innate immune system and serves as a danger signal of stressed or damaged cells. As cytosolic HSP60 levels gradually increase or decrease during carcinogenesis in various organs, HSP60 can be used as a biomarker for the diagnosis and prognosis of preneoplastic and neoplastic lesions. In this review, we summarize recent discoveries on the important roles of HSP60 in various diseases ranging from autoimmune diseases to tumors. Furthermore, small molecules targeting HSP60, which were the target of intensive investigations in the last few years, are also summarized. The possibility of utilizing HSP60 as a new drug target for the treatment of certain diseases is examined.
Export Options
About this article
Cite this article as:
Nakamura Hiroyuki and Minegishi Hidemitsu, HSP60 as a Drug Target, Current Pharmaceutical Design 2013; 19 (3) . https://dx.doi.org/10.2174/1381612811306030441
DOI https://dx.doi.org/10.2174/1381612811306030441 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation
Current Drug Targets CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Biologics in Inflammatory Immune-mediated Systemic Diseases
Current Pharmaceutical Biotechnology Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Current Vascular Pharmacology An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy NKT Cells: A Regulator in Both Innate and Acquired Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Vaccination Against High Blood Pressure
Current Pharmaceutical Design The Role of Chemokines in the Pathogenesis of Rheumatoid Arthritis
Current Rheumatology Reviews Functional Genome and Proteome Analyses of Cutaneous Autoimmune Diseases
Current Pharmaceutical Design Molecular Genetics and Epidemiology of Japanese Type 1 Diabetes
Current Pharmacogenomics Endothelial Chemokines in Autoimmune Disease
Current Pharmaceutical Design Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors
Current Drug Targets Novel Molecular Targets for Systemic Lupus Erythematosus and Other Immune-Complex and T-Cell Mediated Autoimmune Diseases - Update
Medicinal Chemistry Reviews - Online (Discontinued) Basement Membrane Peptides: Functional Considerations and Biomedical Applications in Autoimmunity
Current Medicinal Chemistry Inhibitors of AP-1 and NF-κB Mediated Transcriptional Activation: Therapeutic Potential in Autoimmune Diseases and Structural Diversity
Current Medicinal Chemistry Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Clinical Queries Addressed in Patients with Systemic Autoimmune Diseases. Can Cardiovascular Magnetic Resonance Give the Final Solution?
Inflammation & Allergy - Drug Targets (Discontinued) Biological Therapies of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy